US Patents

GRANTED US PATENTS

1. Orhan, M. D., Avsar, T., Dogan, B., Cacan, G., Calis, S., & Durdagi, S. (2025). "Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor", (DRG-BCL2-1), (U.S. Patent No. 12,384,746 B2). U.S. Patent and Trademark Office.

2. Durdagi, S., Yurtsever, M., Is, Y.S.; Aksoydan, B., Senturk, M. (2025). "Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases, (U.S. Patent No. 12,478,613 B2). U.S. Patent and Trademark Office.

3. Durdagi, S., Yurtsever, M., Is, Y.S., Aksoydan, B., Senturk, M. (2025). "MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases, (U.S. Patent No. 12,528,794 B2). U.S. Patent and Trademark Office.

4. Yurtsever, M., Orhan, M.D., Paksoy, M.N., Aydin, G., Avsar, T., & Durdagi, S. (2025). "DRG-MDM2-6 for use as a novel mouse double minute 2 (MDM2) inhibitor, (U.S. Patent No. 12,502,392 B2). U.S. Patent and Trademark Office.

5. Durdagi, S.; Avsar, T., Orhan, M.D., Cacan, G., Dogan, B., Calis, S. (2025). "Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor", (DRG-BCL2-3), (U.S. Patent No. 12,398,128 B2). U.S. Patent and Trademark Office.

6. Dogan, B., Durdagi, S., Cacan, G., Calis, S., Avsar, T., & Orhan, M. D. (2025). "Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor", (DRG-BCL2-2), (U.S. Patent No. 12,318,368 B2). U.S. Patent and Trademark Office

7. Orhan, M. D., Dogan, B., Calis, S., Cacan, G., Avsar, T., & Durdagi, S. (2025). "Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor", (DRG-BCL2-4), (U.S. Patent No. 12,297,175 B2). U.S. Patent and Trademark Office.

8. Sensoy, Ö., Güzel, M., Kerman, B. E., Üstündağ Okur, N., Mansoor, S., Hanashalshahaby, E., Keskin, E., Durdagi, S., & Kayık, G. (2021). Heterobivalent ligands suitable for use in the treatment of Parkinson’s disease (U.S. Patent No. 11,053,270 B2). U.S. Patent and Trademark Office.